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A common single nucleotide polymorphism (SNP) in the 50 untranslated region (50UTR) of the epidermal growth factor
(EGF) gene modulates the level of transcription of this gene and hence is associated with serum levels of EGF. This
variant may be associated with melanoma risk, but conﬂicting ﬁndings have been reported. An Australian melanoma
case–control sample was typed for the EGFþ 61A4G transversion (rs4444903). The sample comprised 753 melanoma
cases from 738 families stratiﬁed by family history of melanoma and 2387 controls from 645 unselected twin families.
Ancestry of the cases and controls was recorded, and the twins had undergone skin examination to assess total body
nevus count, degree of freckling and pigmentation phenotype. SNP genotyping was carried out via primer extension
followed by matrix-assisted laser desorption time of ﬂight (MALDI-TOF) mass spectroscopy. The EGFþ 61 SNP was
not found to be significantly associated with melanoma status or with development of nevi or freckles. Among
melanoma cases, however, G homozygotes had thicker tumors (p¼ 0.05), in keeping with two previous studies. The
EGF polymorphism does not appear to predispose to melanoma or nevus development, but its significant association
with tumor thickness implies that it may be a useful marker of prognosis.
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The mitogen-activated protein kinase (MAPK) pathway is
a key signal transduction pathway in which extracellular
growth factor signals are transmitted from cell surface re-
ceptors through a cascade of protein kinases to nuclear
transcription factors, which regulate cell proliferation or dif-
ferentiation by altering gene expression. Constitutive acti-
vation of this pathway frequently occurs in malignant
melanoma and appears crucial for autonomous growth of
these tumors (Cohen et al, 2002; Dong et al, 2003; Satya-
moorthy et al, 2003). Recently, somatic mutations of the
BRAF gene have been shown to be the principal mecha-
nism by which the MAPK pathway is activated in (20%–
83%) melanomas (Brose et al, 2002; Davies et al, 2002;
Dong et al, 2003; Maldonado et al, 2003; Pollock et al, 2003;
Satyamoorthy et al, 2003) and (74%–82%) benign mela-
nocytic nevi (Dong et al, 2003; Pollock et al, 2003; Uribe et al,
2003; Yazdi et al, 2003). In the majority of melanomas
without BRAF mutations, the MAPK pathway has been
found to be activated through mutation of members of the
RAS proto-oncogene family, particularly NRAS (van Elsas
et al, 1996). Further support for this notion comes from the
finding that we James et al,1 and others (Meyer et al, 2003),
have shown that germline polymorphisms in the BRAF gene
are significantly associated with melanoma predisposition.
It is reasonable to expect that constitutive natural variation
or somatic mutations in genes encoding other members
of the MAPK pathway could confer inherited susceptibilty to
melanoma, or play a role in melanoma development.
The epidermal growth factor gene (EGF) encodes a lig-
and for the epidermal growth factor receptor (EGFR), a re-
ceptor tyrosine kinase (RTK) that transduces growth signals
to MAPK via RAS and BRAF. Shahbazi et al (2002) reported
a striking association between melanoma risk and G/G
genotype at the þ61 A4G polymorphism in the 50 un-
translated region (50UTR) of EGF (po0.0001). This was
backed up by the finding that peripheral blood mononuclear
cell cultures from individuals homozygous for the G allele
produced significantly more EGF than cells from homozy-
gotes for the A allele, while heterozygotes were found
to produce intermediate levels (Shahbazi et al, 2002). The
Breslow thickness of melanomas at time of presentation
was also greater for G/G homozygotes (p¼0.045). A follow-
up report failed to confirm the association with melanoma
risk, although it did support (p¼0.03) an association be-
tween G/G genotype and thicker tumors (McCarron et al,
2003). In the present study, we sought to extend this work
and to test the hypothesis that the nucleotide 61 poly-
morphism of the EGF gene predisposes to the development
of nevi and freckles as well as melanoma.
Results
There were 3391 individuals genotyped where me-
lanoma status was also known. Case and control genotype
1James MR, Roth RB, Shimm, et al: BRAF polymorphisms and
risk of melanocytic neoplasia. Manuscript in preparation.
Abbreviations: EGF, epidermal growth factor; MAPK, mitogen-ac-
tivated protein kinase; SNP, single nucleotide polymorphism
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frequencies were in Hardy–Weinberg equilibrium. Allele and
genotype frequencies did not differ significantly between
melanoma cases and controls (Table I). Comparing our
sample to those previously studied found that all the control
genotype frequencies could be equated (p¼0.133). The
case genotype frequencies observed in our Australian sam-
ple did not differ significantly from those in a UK sample
described by McCarron et al (2003) (homogeneity of geno-
type frequencies p¼ 0.25; homogeneity of association
with melanoma, p¼0.09), but were significantly different
from that in the UK cases described by Shahbazi et al (2002)
(overall homogeneity p¼ 0.00001).
We did detect a weak association between genotype and
tumor thickness (Table II; Kruskal–Wallis p¼ 0.049), which
was similar in magnitude and direction to that found in both
previous studies. The effect is small: only a fall from 21.4%
in situ melanomas in the A carriers to 16.8% in the G homo-
zygotes. Summarizing the data from the present study
using the same four thickness categories as the two pre-
vious studies led to a small loss of information: the ordinal
logistic regression model obtained p¼0.06. Combining the
present study with the previous two found no evidence for
heterogeneity of association, with the overall association
p¼0.02.
Within the control twin families, there was no association
between EGFþ61 genotype and total body nevus count
(geometric mean count A/A, 98.6; A/G, 100.8; G/G 101.9;
p¼0.56). This was also the case for subtotals of papular,
macular or atypical nevi and for freckling score (data not
shown).
Discussion
We have confirmed a small effect of EGFþ61 genotype on
tumor thickness within a total population sample of me-
lanoma cases from the state of Queensland, Australia.
Since melanoma is so common in our population, surveil-
lance is intense, with the result that the average tumor
thickness in our sample is approximately half that seen in
the two British studies. Despite this difference, roughly the
same pattern of association is seen in the three studies,
with the thickest tumors being from the G/G homozygotes.
We did not see the extreme association with melanoma
risk observed by Shahbazi and coworkers (2002), but our
findings are very close to the study of McCarron et al (2003).
It is difficult to imagine ethnic differences leading to such
a large discrepancy between study findings among cases
only. As noted earlier, control genotype frequencies were
very comparable across all three studies, so one plausible
explanation is Type I error in the initial publication.
There are several lines of evidence that make an asso-
ciation between EGF genotype and melanoma behavior
plausible, in keeping with the functional results presented
by Shahbazi et al (2002). As noted earlier, BRAF somatic
mutations are extremely common in cutaneous melanomas
and benign melanocytic nevi, and, along with NRAS muta-
tion, lead to the constitutive activation of the MAPK path-
way that appears crucial to autonomous growth of these
tumors. Animal models further implicate this pathway in
melanocytic and melanoma pathogenesis. The Tu mela-
noma locus in Xiphophorus is known to be Xmrk, an RTK
homolog of the EGFR (e.g. Wittbrodt et al, 1992; Winkler
et al, 1994). Overexpression of this gene in medakafish
along with injection of TGFa leads to a similar phenotype.
Similarly, Sutton et al (2002) have demonstrated that TGFa
overexpression in mice leads to ocular melanocytosis.
We conclude that EGF polymorphism does not appear to
predispose to melanoma or nevus development, but its
significant association with tumor thickness implies that it
may modify tumor progression.
Table I. CMM and EGFþ 61 genotype in three studies
Shahbazi et al (2002) McCarron et al (2003) Present study
Controls CMMa Controls CMM Controls CMM
A/A 32 (32.3) 21 (15.6) 121 (39.0) 56 (35.2) 883 (33.4) 274 (36.8)
A/G 47 (47.5) 50 (37.0) 131 (42.3) 82 (51.6) 1317 (49.8) 354 (47.5)
G/G 20 (20.2) 64 (47.4) 58 (18.7) 21 (13.2) 446 (16.9) 117 (15.7)
HWE-P 0.718 0.043 0.037 0.288 0.238 0.881
Assoc LOD 3.84 0.53 0.48
p-value 0.00003 0.120 0.14
aCMM, cutaneous malignant melanoma. Count (percent) of each genotype. HWE-P represents p-value from exact test for Hardy–Weinberg equi-
librium. Assoc LOD represents the contingency w2 for each 2  3 table coverted into a LOD score (via inversion of the p-value).
Table II. Breslow thickness of Queensland melanomas versus
EGFþ 61 genotype
Breslow thickness
EGFþ 61 genotype
A/A A/G G/G
In situ 41 (36.6) 58 (51.8) 13 (11.6)
0.1–1.5 mm 145 (35.3) 201 (48.9) 65 (15.8)
1.5–3.5 mm 16 (35.6) 17 (37.8) 12 (26.7)
43.5 mm 4 (50.0) 2 (25.0) 2 (25.0)
Count (percent) of each genotype.
EGF, epidermal growth factor.
EGF POLYMORPHISM AND RISK OF MELANOCYTIC NEOPLASIA 761123 : 4 OCTOBER 2004
Materials and Methods
Participants An Australian case–control panel was made up of
753 melanoma cases from 738 families participating in the
Queensland Familial Melanoma Project (QFMP) (Aitken et al,
1994), and 2387 controls from 645 twin families enrolled in the
Brisbane Twin Nevus Study (BTNS) (Zhu et al, 1999). Ancestry of
the cases and controls was recorded (grandparental country of
birth and ethnicity), along with phenotypic risk factors such as hair
and eye color, and tanning type. Tumor thickness and level were
recorded for the cases.
The BTNS twins and their siblings closest in age have all un-
dergone total body skin examination at age 12 years by a trained
nurse who assessed nevus count, degree of freckling and pig-
mentary phenotypes (Zhu et al, 1999). Parents of the twins were
genotyped, but only self-reported pigmentary characteristics are
available for them. No members of the BTNS have been diagnosed
with melanoma. Approval to undertake this study was granted by
the Human Research Ethics Committee of the Queensland Institute
of Medical Research, and all participants gave their signed in-
formed consent.
Genotyping The functional EGF promoter SNP (rs4444903) was
typed by primer extension and MALDI-TOF mass spectroscopy
(MassARRAY, Sequenom, San Diego, California) as previously des-
cribed (Bansal et al, 2002). SNP identity and other linked informa-
tion may be found in the public databases by using the unique ‘‘rs’’
accession number (NCBI dbSNP, 2003). This SNP had a dropout
rate of o0.5% and few Mendelian errors. Where the latter were
encountered, the entire family was dropped from analysis. To es-
timate error rates due to genotyping technical causes, the SNP
was typed twice on 3268 DNAs independently at different times. Of
the 6536 genotypes, there were only seven unresolved errors (not
attributable to Mendelian, DNA, or other non-technical causes),
which is an error frequency of 0.11%. Of 159 pairs of monozygotic
(MZ) twins in the sample set, none were discordant at this SNP,
further confirming the low genotyping error rate (one member of
each MZ twin pair was set to missing for subsequent association
analysis).
Statistical analysis Allelic association between melanoma and
the SNP was tested using MENDEL 5.0 (Lange et al, 2001), which
implements a measured genotype approach allowing use of family
data as well as unrelated individuals. Combined analysis of the
published studies was performed via log-linear and ordinal logistic
regression analysis using the R statistical package (R Development
Core Team, 2003).
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